Schizophrenia
Conditions
Keywords
Phase Ib, CHINA
Brief summary
This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia
Detailed description
This is a single-center, randomized, double-blind, placebo-controlled, dosion-increasing, Phase Ib clinical study evaluating the safety, tolerability, and pharmacokinetic characteristics of multiple doses of TPN672 maleate in patients with schizophrenia
Interventions
DRUGTPN-672
single dose of TPN-672 maleate tablet
Sponsors
Shanghai Mental Health Center
Jiangsu Kanion Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. 18 years old ≤ age ≤ 65 years old at the time of signing the informed consent form, male or female. 2. 18.5kg/m2 ≤ body mass index (BMI) ≤ 30kg/m2, and weight ≥ 50kg for men and ≥ 45kg for women. 3. Subjects met DSM-5 diagnostic criteria for a confirmed diagnosis of schizophrenia and were stable within the past 6 months as assessed by the investigator. 4. Subjects are currently taking aripiprazole, olanzapine or risperidone monotherapy for schizophrenia at a dose not exceeding the maximum dose specified in the instructions and the dose and frequency of administration have not changed in the last 1 month. 5. Screening period PANSS scale total score \<70, PANSS scale individual score of positive symptom items ≤3, CGI-S score ≤4. 6. Individual scores were ≤1 on the SAS scale, ≤2 on the AIMS scale, and ≤2 on item 4 of the BARS scale, Overall clinical assessment of sedentary inability during the screening period. 7. Female and male subjects of childbearing potential and their spouses must be able to secure effective contraception (medically approved contraception such as IUDs, the pill or condoms) during the study and for 6 months after the end of the drug administration. 8. Subjects and their guardians fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign a written informed consent form, and are willing to complete the entire trial process according to the trial requirements.
Exclusion criteria
1. Subjects met DSM-5 criteria for other psychiatric disorders. 2. Subjects were administered strong inducers/strong inhibitors of CYP2D6, CYP3A4, CYP3A5, CYP2C9 for 5 half-lives prior to the first dose. 3. Subjects were on long-acting antipsychotics for 6 months prior to their first dose. 4. Received electroconvulsive therapy, transcranial magnetic stimulation (rTMS) within 1 month prior to screening 5. Those who answered yes to questions 4 or 5 of the suicidal ideation entry on the Columbia Suicide Scale (C-SSRS) during the screening period, or who were currently or within the past 12 months significantly suicidal, or who were considered to be at risk for suicidal and violent behavior based on the investigator's clinical assessment. 6. Those with abnormal physical examination or vital signs during the screening period that are clinically significant. 7. Abnormal laboratory tests during the screening period that the investigator determines to be clinically significant, e.g., liver: ALT or AST≥ 1.2 times the upper limit of normal; kidney: Cr\> the upper limit of normal value. 8. Prolactin ≥ 5 times the upper limit of normal during the screening period. 9. Screening subjects with systolic blood pressure \<90 mmHg or \>140 mmHg and diastolic blood pressure \< 60mmHg or \>90mmHg. 10. Patients with poorly controlled diabetes (fasting glucose ≥ 10 mmol/L), or are On insulin for diabetes, or at screening with a primary diagnosis of type 2 diabetes. 11. Screening QTc interval \>450ms (men) or 470ms (women), or family history of long QT interval syndrome, or combined cardiac insufficiency, severe arrhythmia or ischemic heart disease requiring medication, congenital heart disease, severe organic heart disease or history of such disease. 12. Combined with convulsive disorders such as epilepsy (except febrile convulsions) 13. Current or previous hyper- or hypothyroidism, Parkinson's disease, malignancy. 14. Tobacco addiction within 1 year prior to screening, with an average of \>10 cigarettes or equivalent per day. 15. Alcohol consumption within 1 year prior to screening, with an average weekly intake of more than 14 units of alcohol (1 unit = 285 ml of beer or 25 ml of spirits or 150 ml of wine) or a positive breath test for alcohol. 16. Persons with a history of drug or substance abuse within 1 year prior to screening or a positive urine drug screen. 17. Subjects who may be hypersensitive to any of the components of this drug. 18. HIV antibody, HBsAg, HCV antibody or positive syphilis serology results. 19. History of significant blood loss or blood loss ≥ 200 ml in the 3 months prior to screening 20. Enrolled in another clinical trial within 3 months prior to screening, or currently participating in a clinical trial. 21. Women who are expecting or breastfeeding. 22. The investigator did not consider it appropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | follow-up visit from the beginning of the dose to the day 14 after the last dose | Incidence of Adverse Events |
| Blood pressure | Day 14 | Safety indicator,Blood pressure is recorded in millimeters of mercury |
| Respiration | Day 14 | Safety indicator，the unit of recording is the number of breaths per minute. |
| Heart rate | Day 14 | Safety indicator，the unit of heart rate is the number of heartbeats per minute. |
| Temperature | Day 14 | Safety indicator,Body temperature is recorded in degrees Celsius |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Positive and Negative Syndrome Scale | Follow-up visit on the day 14 after the last dose | The PANSS consisted of a positive scale of 7 items, a negative scale of 7 items, and a general psychopathology scale of 16 items, for a total of 30 items, and 3 supplementary items to assess the risk of attack. A 7-point scale with increasing levels of psychopathology was used: 1 nothing; 7 a very severe. |
| Clinical Global Impression sions scale | Follow-up visit on the day 14 after the last dose | The scale is divided into 1. overall assessment of disease severity 2. overall degree of improvement. The lower the score, the higher the degree of improvement of the patient. |
| Calgary Depression Scale for Schizophrenia | Follow-up visit on the day 14 after the last dose | There were 9 entries, including mood depression, feelings of hopelessness, self-deprecation, guilt implicated perceptions, pathological guilt, morning depression, early awakening, suicidality, and observed depressive manifestations. The lower the score the less severe the depressive symptoms. |
| Maximum plasma concentration (Cmax) | 240 hours | Blood will be drawn from adult subjects pre-drug application and at 30min, 60min, 90min, 120min, 180min, 240min (4h), 480min (8h），720min (12h)，1440min(24h). |
| 12-lead ECG | Day 14 | Safety indicators, including QTc |
| Serum prolactin ( PRL) | Day 14 | Testing for affected hormone levels |
| Blood coagulation function | Day 14 | Safety indicators, including PT,APTT |
| Time to maximum plasma concentration (Tmax) | 240 hours | Biological sample including blood for PK will be collected at the same time point. |
| Area under the curve (AUC) | 240 hours | Biological sample including blood for PK will be collected at the same time point. |
| steady state minimal concentration（Css_min） | 240hours | Biological sample including blood for PK will be collected at the same time point |
| Elimination half-life (t1/2) | 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours ,days 8-14 after the last dose. | Biological sample including blood for PK will be collected at the same time point. |
Countries
China
Contacts
Primary ContactZhao Binjiang
Outcome results
None listed